Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORKA-002 in moderate-to-severe hidradenitis suppurativa
NCT07783542Phase 2Recruiting
- Sponsor
- Oruka Therapeutics
- Start
- Aug 2026
- Primary completion
- Oct 2028
- Countries
- 2
01
Overview
A Phase 2 trial of ORKA-002 in hidradenitis suppurativa (HS), sponsored by Oruka Therapeutics. Started Aug 2026; status: recruiting.
02
Drugs
ORKA-002
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT07783542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07783542.